Annexon Reports Q4 2025 Financials, Exceeds EPS Estimates, and Details Key Clinical Milestones
ANNX has more than doubled off its 52-week low of $1.285.
Summary
Annexon reported better-than-expected Q4 2025 financial results, a strong cash position extending its runway into H2 2027, and outlined multiple significant clinical milestones for its late-stage pipeline in 2026.
Key Events · Earnings and Guidance · ANNX
-
Q4 2025 Financial Results Exceed Expectations
Annexon reported a net loss of $0.28 per share for the fourth quarter of 2025, outperforming analyst estimates.
-
Strong Cash Position and Extended Runway
The company ended 2025 with approximately $238.3 million in cash, cash equivalents, and short-term investments, providing an anticipated operational runway into the second half of 2027.
-
Pivotal Phase 3 Data for GA Expected in Q4 2026
Topline pivotal Phase 3 ARCHER II trial data for vonaprument in Geographic Atrophy (GA) is anticipated in the fourth quarter of 2026, with potential to be the first vision-preserving therapy for GA.
-
European MAA Filed for GBS Therapy
A Marketing Authorization Application (MAA) for tanruprubart in Guillain-Barré Syndrome (GBS) has been filed in Europe, with U.S./European FORWARD study data expected to support a planned BLA submission in 2026.
Analysis · ANNX · Life Sciences
Annexon's latest 8-K filing provides a comprehensive update on its financial performance and critical pipeline advancements. The company reported a fourth-quarter net loss per share of $0.28, which was better than analyst expectations, indicating improved financial management or revenue performance. Crucially for a biotech, Annexon maintains a strong balance sheet with $238.3 million in cash, cash equivalents, and short-term investments, providing an anticipated operational runway into the second half of 2027. This financial stability supports the continued progression of its late-stage clinical programs. The filing highlights significant upcoming milestones, including pivotal Phase 3 data for vonaprument in Geographic Atrophy expected in Q4 2026, the European MAA filing for tanruprubart in Guillain-Barré Syndrome, and anticipated BLA submission in 2026. Additionally, Proof-of-Concept data for the oral C1 inhibitor ANX1502 is expected in 2026. These clinical updates are vital for the company's long-term value creation and represent key catalysts for investors.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANNX was trading at $4.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $717.9M. The 52-week trading range was $1.29 to $7.18. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.